SMN1 and hepatocellular carcinoma: We observed that rosuvastatin reduced the number of SMA-positive arteries in HCC compared with untreated HCC livers (12 ± 5.5/mm2/section for treated HCC versus 23.7 ± 4.3/mm2/section for untreated HCC, P < .05) (Figures 4(a) and 4(b)).